Margin Expansion Watch: Can Q2 Sustain Q1's 20%+ Growth Amid Oversold Valuation?
Amara Raja's Q1 FY27 delivered solid 21% revenue growth on strong EV and aftermarket demand. Q2 expectations hinge on whether the company sustains the growth trajectory, proves margin expansion roadmap, and capitalizes on lithium/cell manufacturing investments—all while trading 17% below consensus targets.
The Setup: Growth at Risk to Margin Proof
Amara Raja Batteries enters Q2 FY27 (September 2026) on the back of a robust Q1—21% consolidated revenue growth to ₹4,214.5 Cr, with PAT climbing 16% to ₹190.9 Cr. But the print revealed a margin squeeze: consolidated EBITDA margin compressed despite higher volumes, signaling that leverage from capacity and cost reduction is the key watch for Q2. The street's consensus rests on two big bets: (1) the company's stated margin expansion roadmap—from 11.5% in Q1 FY26 toward 14% by FY27E, and (2) continued double-digit revenue growth in a buoyant EV/two-wheeler battery market expected to hit 1.8–1.9 lakh units in CY2026. Q2 will test both.
~₹3,750–3,850 Cr
18–22% YoY growth; Q1 FY27 was ₹4,041 Cr (+21% YoY). Q2 typically runs slightly softer seasonally, but buoyant OEM/EV demand should offset.
~12.5–13.0%
vs. 11.5% in Q1 FY26. Expansion hinges on tubular plant ramp, lower antimony costs, and 2W battery strength.
~15–20%
Q1 FY27 PAT grew 16% YoY (consolidated). Margin expansion more important than volume growth this quarter.
₹693.75 (current)
Stock trades 17–35% below analyst consensus targets (Nuvama ₹1,120 Buy, Anand Rathi ₹1,080 Hold, Motilal Oswal ₹944 Neutral). RSI 25.4 signals oversold.
What a Strong vs. Weak Print Looks Like
Strong quarter: Revenue tracking the 18–22% YoY growth band (₹3,750–3,850 Cr); EBITDA margin expanding to 12.8%+ (showing tubular ramp traction and cost discipline); PAT growth accelerating to 18%+; management guidance affirming full-year 14% margin target. Any commentary on lithium/cell manufacturing ramp or new OEM wins would be a bonus. Weak quarter: Revenue growth dropping to low teens (<15% YoY) or, worse, a margin miss—EBITDA contracting to 11.5% or below. This would signal either (1) market softness in 2W/4W segments, (2) antimony/raw material pressure persisting, or (3) execution slippage on the cost roadmap. Guidance cuts would spook the market given the stock's 60%+ decline from ATH.
On Track for FY27 Guidance?
Q1 FY27 delivered a 21% revenue growth and 16% PAT growth, putting the company on pace for double-digit growth in a strong EV cycle. Analysts model 14% EBITDA margins achievable in FY27E—a jump from the 11.5% seen in Q1 FY26—assuming tubular plant ramp-up, stabilizing raw material costs, and export momentum hold. The Board's investment of ₹500 Cr in cell manufacturing (announced Aug 2026) signals confidence in the long-term Li-ion/LFP opportunity, but near-term execution (meeting margin and growth targets without capex drag) is paramount. Q2 will be the inflection: if margins expand in-line, FY27 targets remain achievable. If not, the full-year outlook will face pressure.
Since Last Quarter: Key Filings & Ops Updates
1 · Management Succession: New CBOs Appointed (Oct 26, 2026)
Amara Raja appointed Mr. Preetam Ganguly as Chief Business Officer – Industrial. Part of planned succession; no loss of continuity flagged. Watch for any change in strategy or capex execution on the lithium/cell push.
2 · Board Meeting Nov 2, 2026 (Trading Window Closure Oct 1 – Nov 4)
Standard Q2 results announcement meeting. Window closure Oct 1 – Nov 4 is routine. Board will consider standalone and consolidated unaudited financials.
3 · Investment Approvals: ₹500 Cr Gigafactory Capex (Aug 2026)
Amara Raja Advanced Cell Technologies (subsidiary) commissioned Customer Qualification Plant in Telangana with ₹500 Cr outlay. Strategic for long-term Li-ion optionality, but capex intensity will pressure cash/ROI near-term. Watch for quarterly capex rundown in the results.
4 · Regulatory: APPCB Closure Orders Revoked (Jul 2026)
Andhra Pradesh Pollution Control Board revoked prior closure orders on manufacturing facilities (Karakambadi, Nunegundlapalle). Company withdrew related writ petitions. Operationally clear; removes prior uncertainty on production licences.
5 · Minor Tax Penalty: ₹13.3 L GST (Jul 2026)
Routine administrative penalty for address mismatch in tax invoices. Non-material; operational risk low.
What to Watch on November 2, 2026
1. Margin trajectory: Did EBITDA margin expand to 12.5%+ YoY (Q1 FY26 baseline: 11.5%)? Any commentary on tubular plant ramp efficiency and antimony/commodity cost outlook for H2 FY27? 2. Revenue growth pace: Is growth still in the 18–22% YoY band, or has EV/2W demand softened? Any color on OEM order flow and export traction? 3. Cell manufacturing capex rundown: What's the quarterly capex burn on the ₹500 Cr gigafactory? Any progress updates or revised timeline? 4. New CBO impact: Management commentary on the recent appointment—any hints on strategic shift or acceleration in new product (Li-ion/LFP cells) rollout? 5. Guidance reaffirmation: Will the Board reaffirm FY27E margin and growth targets, or revise? A cut would be a red flag; reaffirmation would support the ₹950+ target-price consensus.
Amara Raja Batteries heads into Q2 FY27 at a critical juncture: revenue growth remains intact (Q1 showed 21% YoY), but the stock has crashed 60% from its all-time high, pricing in significant execution risk on the margin expansion and capex payoff. The EV battery market tailwind is real (1.8–1.9 lakh passenger EV units expected in CY2026; 256.3 GWh demand by 2032), but near-term, the company must prove it can grow revenue AND expand margins simultaneously—a tough balancing act when raw material costs and capex intensity are headwinds.
Analysts remain cautiously constructive (Nuvama Buy, Anand Rathi/ICICI/Motilal Oswal Hold), but the 17% gap between stock price and consensus targets suggests the market is pricing a margin miss or slower-than-expected cell ramp. Q2 results on November 2 will be the inflection: if EBITDA margins expand to 12.5%+, growth sustains, and management reaffirms FY27 targets, the oversold positioning could trigger a sharp rebound. A miss on margins or guidance would confirm the bear case.
Bottom line: A strong quarter (growth in-band, margin expansion, guidance reaffirmed) would validate the ₹950–1,000 fair value from consensus analysts and likely spark short-covering. A weak quarter (growth below 15%, margin contraction, guidance cut) would extend the downside to ₹600–650. The stock's RSI of 25.4 (oversold) suggests upside optionality, but execution is everything.
Informational and educational content only. Not investment advice.